A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

Trial Identifier: TCD17710
Sponsor: Sanofi
Start Date: May 2023
Primary Completion Date: May 2025
Study Completion Date: May 2025
Condition: Myeloma; Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, New South Wales WOLLONGONG, New South Wales, AUSTRALIA, 2500
AUSTRALIA, Victoria RICHMOND, Victoria, AUSTRALIA, 3121
Belgium Antwerpen, Belgium, 2020
BELGIUM Anderlecht, BELGIUM, 1070
BELGIUM ANTWERP, BELGIUM, 2060
BELGIUM Antwerpen, BELGIUM, 2030
CZECHIA BRNO, CZECHIA, 625 00
CZECHIA OSTRAVA, CZECHIA, 708 52
HUNGARY BUDAPEST, HUNGARY, 1085
ITALY, Lombardia ROZZANO, Lombardia, ITALY, 20089
SPAIN, Barcelona Barcelona, SPAIN, 08036
SPAIN, Cantabria Santander, Cantabria, SPAIN, 39008
SPAIN, Cataluña Badalona, Cataluña, SPAIN, 08916
UNITED KINGDOM, Birmingham BIRMINGHAM, Birmingham, UNITED KINGDOM, B15 2TH
UNITED KINGDOM, Manchester MANCHESTER, Manchester, UNITED KINGDOM, M20 4BX
UNITED KINGDOM, Not Known LONDON, Not Known, UNITED KINGDOM, NW1 2BU